MLTX
MoonLake Immunotherapeutics
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
MoonLake Immunotherapeutics
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Expected move
Inputsspot 11.47exp Nov 20ATM strike 11ATM straddle 2.22IV 110%
No thesis.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
MoonLake Immunotherapeutics
11.47
pre 11.53 −2.12%
Tall tick = annual report · Source: EDGAR
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for MoonLake Immunotherapeutics.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for MoonLake Immunotherapeutics.
—
—
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| BVF | $311.5M | 21.27% | 0.00% |
| Deep Track Capital | $136.3M | 9.30% | +9.21% |
| T. Rowe Price | $83.3M | 5.69% | new |
| D. E. Shaw | $65.5M | 4.47% | +40.78% |
| Cormorant | $62.4M | 4.26% | −28.46% |
| Manager | Value | % base | |
|---|---|---|---|
| BVF | $311.5M | 21.27% | 0.00% |
| Deep Track Capital | $136.3M | 9.30% | +9.21% |
| T. Rowe Price | $83.3M | 5.69% | new |
| D. E. Shaw | $65.5M | 4.47% | +40.78% |
| Cormorant | $62.4M | 4.26% | −28.46% |